Share Price and Basic Stock Data
Last Updated: December 8, 2025, 3:53 pm
| PEG Ratio | -1.88 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Aspira Pathlab & Diagnostics Ltd operates within the Hospitals and Medical Services sector, a space that has seen significant growth, particularly following the pandemic. Currently priced at ₹65.3, the company’s market capitalization stands at ₹67.2 Cr. Over the past few years, revenue trends have shown volatility. For instance, total sales reported for FY 2023 were ₹14.46 Cr, a decline from ₹19.54 Cr in FY 2022. However, the trailing twelve months (TTM) figures indicate a rebound, with revenues climbing to ₹22.62 Cr. This suggests that the company may be regaining its footing after a challenging period. Quarterly sales in the recent September 2023 quarter were ₹3.32 Cr, reflecting a modest recovery from the previous quarter’s ₹2.60 Cr. This fluctuation in revenue highlights both the challenges and the potential for growth in a sector that remains essential for public health.
Profitability and Efficiency Metrics
Examining profitability metrics reveals a mixed picture for Aspira Pathlab. The reported net profit for FY 2025 is ₹2.07 Cr, up from a loss of ₹0.09 Cr in FY 2023. This turnaround is commendable but is accompanied by fluctuating operating margins, which stood at 11.07% for FY 2023 and have shown improvement to 16.18% in FY 2025. The company’s operating profit margin (OPM) has been variable, reflecting operational challenges, especially in recent quarters where it dipped below zero. The return on equity (ROE) at 33.6% appears strong, indicating effective management of shareholder funds. However, the return on capital employed (ROCE) of 17.4% suggests room for improvement in utilizing capital resources efficiently. This combination of rising profits alongside fluctuating margins indicates that while the company is moving in the right direction, sustained focus on operational efficiency will be crucial.
Balance Sheet Strength and Financial Ratios
Aspira’s balance sheet exhibits a cautious approach to leverage, with total borrowings recorded at ₹3.13 Cr against reserves of ₹4.13 Cr. This translates to a low debt-to-equity ratio of 0.09, suggesting that the company is not overly reliant on debt for its operations, which is a positive indicator for risk-averse investors. The interest coverage ratio (ICR) stands at 11.27x, which indicates that the company can comfortably meet its interest obligations. However, the price-to-book value (P/BV) ratio of 7.21x suggests that the stock may be trading at a premium, which could be a point of concern for potential investors looking for value. Additionally, the cash conversion cycle (CCC) of 16.30 days reflects a reasonable operational efficiency, indicating that the company is managing its inventory and receivables effectively. Overall, the balance sheet appears stable, although investors should monitor how effectively the company can convert its operational efficiency into sustained profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Aspira Pathlab reveals a significant public stake of 81.61%, with promoter holdings declining slightly to 18.39%. This shift may indicate a gradual dilution of control by the promoters, which could be interpreted in different ways by investors. The increase in the number of shareholders from 1,300 in December 2022 to 1,755 in September 2025 suggests growing interest and confidence in the company among retail investors. However, the absence of foreign institutional investors (FIIs) or domestic institutional investors (DIIs) implies a lack of institutional backing, which could be a potential red flag for some. While the public stake reflects a strong retail interest, the decline in promoter shareholding could raise questions about long-term commitment from the management team. This dynamic could impact investor sentiment and should be watched closely.
Outlook, Risks, and Final Insight
Looking ahead, Aspira Pathlab faces both opportunities and risks. The recent uptick in revenues and profitability suggests a potential recovery, yet the volatility in operating margins raises concerns about operational stability. The healthcare sector is inherently subject to regulatory changes, competitive pressures, and evolving consumer demands, which could impact revenue streams. Moreover, the lack of institutional investment could limit the stock’s appeal to larger investors, affecting liquidity. On the positive side, the company’s solid balance sheet and low debt levels provide a buffer against economic fluctuations. Investors should weigh the potential for growth against these risks, keeping an eye on operational efficiency and market conditions. For those considering an investment, it may be prudent to adopt a watchful approach, monitoring not just financial metrics but also broader industry trends that could influence Aspira’s performance in the coming quarters.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Aspira Pathlab & Diagnostics Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 40.9 Cr. | 122 | 195/120 | 8.34 | 117 | 2.87 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 18.0 Cr. | 17.1 | 35.5/15.5 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 10.2 Cr. | 9.89 | 20.9/9.57 | 114 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 115 Cr. | 61.6 | 98.7/55.2 | 25.5 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 20.6 Cr. | 3.82 | 7.29/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 26,198.43 Cr | 755.39 | 93.74 | 99.39 | 0.35% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.97 | 3.71 | 4.37 | 3.41 | 2.60 | 3.32 | 3.46 | 3.82 | 4.64 | 6.18 | 5.41 | 5.78 | 5.25 |
| Expenses | 2.79 | 3.25 | 3.56 | 3.26 | 2.92 | 3.68 | 3.83 | 3.95 | 4.29 | 4.83 | 4.65 | 4.73 | 4.44 |
| Operating Profit | 0.18 | 0.46 | 0.81 | 0.15 | -0.32 | -0.36 | -0.37 | -0.13 | 0.35 | 1.35 | 0.76 | 1.05 | 0.81 |
| OPM % | 6.06% | 12.40% | 18.54% | 4.40% | -12.31% | -10.84% | -10.69% | -3.40% | 7.54% | 21.84% | 14.05% | 18.17% | 15.43% |
| Other Income | 0.06 | 0.07 | 0.12 | 0.07 | 0.10 | 0.14 | 0.10 | 0.08 | 0.09 | 0.08 | 0.09 | 0.13 | 0.11 |
| Interest | 0.11 | 0.11 | 0.10 | 0.10 | 0.10 | 0.10 | 0.09 | 0.08 | 0.08 | 0.08 | 0.09 | 0.09 | 0.09 |
| Depreciation | 0.42 | 0.40 | 0.39 | 0.38 | 0.39 | 0.39 | 0.38 | 0.38 | 0.38 | 0.36 | 0.39 | 0.37 | 0.37 |
| Profit before tax | -0.29 | 0.02 | 0.44 | -0.26 | -0.71 | -0.71 | -0.74 | -0.51 | -0.02 | 0.99 | 0.37 | 0.72 | 0.46 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | -0.29 | 0.02 | 0.44 | -0.26 | -0.72 | -0.71 | -0.74 | -0.50 | -0.02 | 0.99 | 0.38 | 0.72 | 0.47 |
| EPS in Rs | -0.28 | 0.02 | 0.43 | -0.25 | -0.70 | -0.69 | -0.72 | -0.49 | -0.02 | 0.96 | 0.37 | 0.70 | 0.46 |
Last Updated: August 19, 2025, 11:05 pm
Below is a detailed analysis of the quarterly data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.25 Cr.. The value appears to be declining and may need further review. It has decreased from 5.78 Cr. (Mar 2025) to 5.25 Cr., marking a decrease of 0.53 Cr..
- For Expenses, as of Jun 2025, the value is 4.44 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 4.73 Cr. (Mar 2025) to 4.44 Cr., marking a decrease of 0.29 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.81 Cr.. The value appears to be declining and may need further review. It has decreased from 1.05 Cr. (Mar 2025) to 0.81 Cr., marking a decrease of 0.24 Cr..
- For OPM %, as of Jun 2025, the value is 15.43%. The value appears to be declining and may need further review. It has decreased from 18.17% (Mar 2025) to 15.43%, marking a decrease of 2.74%.
- For Other Income, as of Jun 2025, the value is 0.11 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.11 Cr., marking a decrease of 0.02 Cr..
- For Interest, as of Jun 2025, the value is 0.09 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.09 Cr..
- For Depreciation, as of Jun 2025, the value is 0.37 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.37 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.46 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.46 Cr., marking a decrease of 0.26 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00%.
- For Net Profit, as of Jun 2025, the value is 0.47 Cr.. The value appears to be declining and may need further review. It has decreased from 0.72 Cr. (Mar 2025) to 0.47 Cr., marking a decrease of 0.25 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.46. The value appears to be declining and may need further review. It has decreased from 0.70 (Mar 2025) to 0.46, marking a decrease of 0.24.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:52 am
| Metric | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.76 | 4.36 | 7.64 | 8.42 | 15.21 | 19.54 | 14.46 | 13.20 | 22.00 | 22.62 |
| Expenses | 0.02 | 0.14 | 0.23 | 3.34 | 8.24 | 10.88 | 10.25 | 11.69 | 13.16 | 12.86 | 14.38 | 18.44 | 18.65 |
| Operating Profit | -0.02 | -0.14 | -0.23 | -2.58 | -3.88 | -3.24 | -1.83 | 3.52 | 6.38 | 1.60 | -1.18 | 3.56 | 3.97 |
| OPM % | -339.47% | -88.99% | -42.41% | -21.73% | 23.14% | 32.65% | 11.07% | -8.94% | 16.18% | 17.55% | |||
| Other Income | 0.02 | 0.21 | 0.32 | 0.31 | 0.22 | 0.25 | 0.29 | 0.20 | 0.09 | 0.32 | 0.42 | 0.36 | 0.41 |
| Interest | 0.00 | 0.00 | 0.05 | 0.26 | 0.80 | 0.96 | 1.01 | 0.89 | 0.37 | 0.42 | 0.37 | 0.35 | 0.35 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.20 | 1.12 | 1.23 | 1.66 | 1.44 | 1.64 | 1.59 | 1.54 | 1.49 | 1.49 |
| Profit before tax | 0.00 | 0.07 | 0.04 | -2.73 | -5.58 | -5.18 | -4.21 | 1.39 | 4.46 | -0.09 | -2.67 | 2.08 | 2.54 |
| Tax % | 57.14% | 25.00% | 0.00% | 0.00% | 0.00% | 0.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | ||
| Net Profit | 0.00 | 0.02 | 0.03 | -2.72 | -5.58 | -5.18 | -4.24 | 1.38 | 4.46 | -0.09 | -2.67 | 2.07 | 2.56 |
| EPS in Rs | 0.00 | 0.09 | 0.13 | -5.24 | -10.75 | -6.32 | -4.56 | 1.34 | 4.33 | -0.09 | -2.59 | 2.01 | 2.49 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 50.00% | -9166.67% | -105.15% | 7.17% | 18.15% | 132.55% | 223.19% | -102.02% | -2866.67% | 177.53% |
| Change in YoY Net Profit Growth (%) | 0.00% | -9216.67% | 9061.52% | 112.32% | 10.98% | 114.40% | 90.64% | -325.21% | -2764.65% | 3044.19% |
Aspira Pathlab & Diagnostics Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 10 years from 2015-2016 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 4% |
| TTM: | 48% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 59% |
| 5 Years: | 20% |
| 3 Years: | -23% |
| TTM: | 230% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 26% |
| 3 Years: | 13% |
| 1 Year: | 99% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | -3% |
| Last Year: | 24% |
Last Updated: September 5, 2025, 2:26 pm
Balance Sheet
Last Updated: December 4, 2025, 2:26 am
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 2.25 | 2.25 | 5.19 | 5.19 | 8.19 | 9.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 | 10.29 |
| Reserves | 0.19 | 1.36 | 1.39 | 0.72 | -4.86 | -7.93 | -10.42 | -6.91 | -2.43 | -2.47 | -5.08 | -3.01 | 4.13 |
| Borrowings | 0.00 | 0.00 | 2.62 | 7.29 | 11.36 | 12.52 | 13.80 | 7.01 | 8.85 | 8.24 | 7.71 | 8.13 | 3.13 |
| Other Liabilities | 0.03 | 0.21 | 0.03 | 1.66 | 0.84 | 2.02 | 1.67 | 1.39 | 1.42 | 1.28 | 1.79 | 2.11 | 2.61 |
| Total Liabilities | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 20.16 |
| Fixed Assets | 0.00 | 0.00 | 0.04 | 7.79 | 7.91 | 8.90 | 8.70 | 7.75 | 9.57 | 8.01 | 6.79 | 6.53 | 6.71 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.25 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.13 | 0.00 |
| Other Assets | 0.62 | 3.82 | 6.25 | 6.82 | 4.62 | 5.90 | 5.64 | 4.03 | 8.56 | 9.33 | 7.92 | 10.86 | 13.45 |
| Total Assets | 0.62 | 3.82 | 6.29 | 14.86 | 12.53 | 14.80 | 14.34 | 11.78 | 18.13 | 17.34 | 14.71 | 17.52 | 20.16 |
Below is a detailed analysis of the balance sheet data for Aspira Pathlab & Diagnostics Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 10.29 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 10.29 Cr..
- For Reserves, as of Sep 2025, the value is 4.13 Cr.. The value appears strong and on an upward trend. It has increased from -3.01 Cr. (Mar 2025) to 4.13 Cr., marking an increase of 7.14 Cr..
- For Borrowings, as of Sep 2025, the value is 3.13 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 8.13 Cr. (Mar 2025) to 3.13 Cr., marking a decrease of 5.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 2.61 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 2.11 Cr. (Mar 2025) to 2.61 Cr., marking an increase of 0.50 Cr..
- For Total Liabilities, as of Sep 2025, the value is 20.16 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.52 Cr. (Mar 2025) to 20.16 Cr., marking an increase of 2.64 Cr..
- For Fixed Assets, as of Sep 2025, the value is 6.71 Cr.. The value appears strong and on an upward trend. It has increased from 6.53 Cr. (Mar 2025) to 6.71 Cr., marking an increase of 0.18 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 0.13 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 0.13 Cr..
- For Other Assets, as of Sep 2025, the value is 13.45 Cr.. The value appears strong and on an upward trend. It has increased from 10.86 Cr. (Mar 2025) to 13.45 Cr., marking an increase of 2.59 Cr..
- For Total Assets, as of Sep 2025, the value is 20.16 Cr.. The value appears strong and on an upward trend. It has increased from 17.52 Cr. (Mar 2025) to 20.16 Cr., marking an increase of 2.64 Cr..
Notably, the Reserves (4.13 Cr.) exceed the Borrowings (3.13 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.02 | -0.14 | -2.85 | -9.87 | -15.24 | -15.76 | -15.63 | -3.49 | -2.47 | -6.64 | -8.89 | -4.57 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2012 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 43.22 | 29.30 | 38.22 | 26.01 | 40.80 | 83.87 | 59.07 | 61.94 | 38.99 | |||
| Inventory Days | 312.86 | 103.88 | 45.22 | 51.36 | 51.35 | 46.50 | 58.40 | 62.69 | 50.31 | |||
| Days Payable | 730.00 | 64.58 | 46.84 | 73.37 | 91.60 | 70.91 | 51.10 | 101.70 | 73.00 | |||
| Cash Conversion Cycle | -373.92 | 68.61 | 36.60 | 4.00 | 0.55 | 59.46 | 66.37 | 22.93 | 16.30 | |||
| Working Capital Days | -2,199.61 | -5.86 | -96.03 | -127.01 | 16.32 | 69.30 | 48.72 | 25.16 | 14.10 | |||
| ROCE % | 0.00% | 1.82% | -25.39% | -38.41% | -34.49% | -25.15% | 19.77% | 35.65% | 2.01% | -15.87% | 17.37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | 1.97 |
| Diluted EPS (Rs.) | 1.97 |
| Cash EPS (Rs.) | 3.46 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 11.82 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 11.82 |
| Revenue From Operations / Share (Rs.) | 21.37 |
| PBDIT / Share (Rs.) | 3.80 |
| PBIT / Share (Rs.) | 2.35 |
| PBT / Share (Rs.) | 2.01 |
| Net Profit / Share (Rs.) | 2.01 |
| NP After MI And SOA / Share (Rs.) | 1.97 |
| PBDIT Margin (%) | 17.79 |
| PBIT Margin (%) | 11.00 |
| PBT Margin (%) | 9.42 |
| Net Profit Margin (%) | 9.42 |
| NP After MI And SOA Margin (%) | 9.19 |
| Return on Networth / Equity (%) | 16.62 |
| Return on Capital Employeed (%) | 16.03 |
| Return On Assets (%) | 11.58 |
| Long Term Debt / Equity (X) | 0.09 |
| Total Debt / Equity (X) | 0.09 |
| Current Ratio (X) | 2.26 |
| Quick Ratio (X) | 2.05 |
| Interest Coverage Ratio (X) | 11.27 |
| Interest Coverage Ratio (Post Tax) (X) | 6.97 |
| Enterprise Value (Cr.) | 86.79 |
| EV / Net Operating Revenue (X) | 3.95 |
| EV / EBITDA (X) | 22.18 |
| MarketCap / Net Operating Revenue (X) | 3.99 |
| Price / BV (X) | 7.21 |
| Price / Net Operating Revenue (X) | 3.99 |
| EarningsYield | 0.02 |
After reviewing the key financial ratios for Aspira Pathlab & Diagnostics Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 25, the value is 3.46. This value is within the healthy range. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 11.82. No previous period data is available for comparison.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 21.37. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 3.80. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 25, the value is 2.35. This value is within the healthy range. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 2.01. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 1.97. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBDIT Margin (%), as of Mar 25, the value is 17.79. This value is within the healthy range. No previous period data is available for comparison.
- For PBIT Margin (%), as of Mar 25, the value is 11.00. This value is within the healthy range. No previous period data is available for comparison.
- For PBT Margin (%), as of Mar 25, the value is 9.42. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Net Profit Margin (%), as of Mar 25, the value is 9.42. This value is within the healthy range. No previous period data is available for comparison.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 9.19. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 25, the value is 16.62. This value is within the healthy range. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 25, the value is 16.03. This value is within the healthy range. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 25, the value is 11.58. This value is within the healthy range. No previous period data is available for comparison.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 0.2. No previous period data is available for comparison.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.09. This value is within the healthy range. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 25, the value is 2.26. This value is within the healthy range. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 25, the value is 2.05. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 11.27. This value is within the healthy range. No previous period data is available for comparison.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 6.97. This value is within the healthy range. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 25, the value is 86.79. No previous period data is available for comparison.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 3.95. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 25, the value is 22.18. This value exceeds the healthy maximum of 15. No previous period data is available for comparison.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 25, the value is 7.21. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.99. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Aspira Pathlab & Diagnostics Ltd:
- Net Profit Margin: 9.42%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 16.03% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 16.62% (Industry Average ROE: 14.16%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 6.97
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 2.05
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 19.7 (Industry average Stock P/E: 77.44)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.09
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 9.42%
Aspira Pathlab & Diagnostics Ltd: Intrinsic Value & Share Price Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | Flat No.2, R.D. Shah Building, Mumbai Maharashtra 400086 | info@aspiradiagnostics.com http://www.aspiradiagnostics.com |
| Management | |
|---|---|
| Name | Position Held |
| Dr. Haseeb Drabu | Chairman & Ind.Director |
| Dr. Pankaj J Shah | Managing Director & CEO |
| Mr. Nikunj Mange | Executive Director |
| Mr. Manas Mengar | Independent Director |
| Mr. Avinash C Mahajan | Independent Director |
| Mrs. Mangala K Prabhu | Independent Director |
FAQ
What is the intrinsic value of Aspira Pathlab & Diagnostics Ltd?
Aspira Pathlab & Diagnostics Ltd's intrinsic value (as of 08 December 2025) is 75.62 which is 15.80% higher the current market price of 65.30, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 67.2 Cr. market cap, FY2025-2026 high/low of 107/50.5, reserves of ₹4.13 Cr, and liabilities of 20.16 Cr.
What is the Market Cap of Aspira Pathlab & Diagnostics Ltd?
The Market Cap of Aspira Pathlab & Diagnostics Ltd is 67.2 Cr..
What is the current Stock Price of Aspira Pathlab & Diagnostics Ltd as on 08 December 2025?
The current stock price of Aspira Pathlab & Diagnostics Ltd as on 08 December 2025 is 65.3.
What is the High / Low of Aspira Pathlab & Diagnostics Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Aspira Pathlab & Diagnostics Ltd stocks is 107/50.5.
What is the Stock P/E of Aspira Pathlab & Diagnostics Ltd?
The Stock P/E of Aspira Pathlab & Diagnostics Ltd is 19.7.
What is the Book Value of Aspira Pathlab & Diagnostics Ltd?
The Book Value of Aspira Pathlab & Diagnostics Ltd is 14.0.
What is the Dividend Yield of Aspira Pathlab & Diagnostics Ltd?
The Dividend Yield of Aspira Pathlab & Diagnostics Ltd is 0.00 %.
What is the ROCE of Aspira Pathlab & Diagnostics Ltd?
The ROCE of Aspira Pathlab & Diagnostics Ltd is 17.4 %.
What is the ROE of Aspira Pathlab & Diagnostics Ltd?
The ROE of Aspira Pathlab & Diagnostics Ltd is 33.6 %.
What is the Face Value of Aspira Pathlab & Diagnostics Ltd?
The Face Value of Aspira Pathlab & Diagnostics Ltd is 10.0.